23 Anti-CD20 therapy: where are we today?
Explain that early use of rituximab/b-cell depletion may substantially reduce the steroid requirement for many SLE patients .Explain the potential advantage of a fully humanised B-cell depleting agent
Authors
- Richard Alan Furie (ORCID: https://orcid.org/0000-0001-6712-1585)
Institutions
- Hofstra University (US)
Publication Details
- Journal
- Abstracts
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/lupus-2025-la.23
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00